FABP4 and fatty liver disease: Among the synthetic FABP4 inhibitors developed to date [71,144,145,146,147,148,149,150,151,152], BMS309403, which competitively inhibits the binding of endogenous fatty acids [29,71,146], protects against several metabolic disturbances [29,153], including fatty liver disease [28,29].